A Big Boost for Amgen

An FDA vote against dosing limits for Epogen lifts "a major cloud of uncertainty" over the stock, according to one Wall Street pro

Amgen (AMGN) found relief on word that the Food and Drug Administration voted against setting dosing limits on the company's blockbuster anemia drug Epogen for kidney disease patients. Shares of Amgen rose 4.7% to $56.46 on heavy trading volume on the Nasdaq on Sept. 12.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.